Publications

Pubmed logo      Google Scholar

2015

  1. Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, Messina A, Huang Z, We J, Oddo S. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer’s disease. J Neurosci, in press.
    **Journal impact factor: 6.3    Number of times cited: 0 

  2. Talboom JS, Velazquez R, Oddo S. The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease. Aging and Mechanisms of Disease, in press.
    **Journal impact factor: N/A    Number of times cited: 0 

  3. Mastroeni D, Delvaux E, Nolz J, Tan Y, Grover, A, Oddo S, Coleman P. Aberrant Intracellular Localization of H3k4me3 Demonstrates an Early Epigenetic Phenomenon in Alzheimer's Disease. Neurobiol of Aging, in press.
    **Journal impact factor: 5.013    Number of times cited: 0 

  4. Caccamo A, Shaw DM, Guarino F, Messina A, Walker AW, Oddo S. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDA C-terminal fragment of TDP-43. Hum Mol Genet. 2015, in press.
    **Journal impact factor: 6.3    Number of times cited: 0 

  5. Richardson A, Galvan V, Lin AL, Oddo S. How Longevity Research Can Lead To Therapies for Alzheimer's Disease: The Rapamycin Story. Exp Gerontol. 2015 Aug;68:51-8.
    **Journal impact factor: 3.529Number of times cited: 0


2014

  1. Branca C, Wisely EV, Hartman LK, Caccamo A, Oddo S.  Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease.  Neurobiol of Aging. 2014 Dec;35(12):2726-35.
    **Journal impact factor: 6.189    Number of times cited: 0 

  2. Caccamo A, De Pinto V, Messina A, Branca C, Oddo S.  Genetic reduction of mTOR ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.  J Neurosci. 2014 Jun 4;34(23):7988-98.
    **Journal impact factor: 6.9    Number of times cited: 4            

  3. Wisely EV, Xiang YK, Oddo S.  Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies.  Hum Mol Genet. 2014 Aug 1;23(15):4024-34
    **Journal impact factor: 7.692    Number of times cited: 2 

  4. Orr ME, Salinas A, Buffenstein R, Oddo S.  Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer’s disease pathology.  Neurobiol Aging. 2014 Jun;35(6):1233-42.
    **Journal impact factor: 6.189    Number of times cited: 4 

  5. Edrey YH, Oddo S, Cornelius C, Caccamo A, Calabrese V, Buffenstein R. Oxidative damage and amyloid-β metabolism in brain regions of the longest-lived rodents. J Neurosci Res. 2014 Feb;92(2):195-205.
    **Journal impact factor: 2.974    Number of times cited: 4

  6. Medina DX, Miranda EO, Oddo S.  Accumulation of C-terminal fragments of TDP-43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice.  Neurobiol Aging. 2014 Jan;35(1):79-87.
    **Journal impact factor: 6.189    Number of times cited: 6 


2013

  1. Orr ME and Oddo S.  Autophagic/lysosomal dysfunction in Alzheimer’s disease.  Alzheimers Res Ther. 2013 Oct 29;5(5):53.
    **Journal impact factor: 4.390    Number of times cited: 8

  2. Edrey YH, Medina DX, Gaczynska M, Osmulski PA, Oddo S, Caccamo A, Buffenstein R.  Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease.  Neurobiol Aging. 2013 Oct;34(10):2352-60
    **Journal impact factor: 6.189    Number of times cited: 6 

  3. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S.  mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer’s disease and other tauopathies.  Aging Cell. 2013 Jun;12(3):370-80
    **Journal impact factor: 7.15Number of times cited: 41

  4. Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, Matt L, Hell JW, Wisely EV, Oddo S, Xiang YK.  β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer's disease models.  J Biol Chem. 2013 Apr 12;288(15):10298-307.
    **Journal impact factor: 4.773    Number of times cited: 18

  5. Caccamo A, Medina DX, Oddo S. Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: Implications for aging, stress and TDP-43 proteinopathies.  J Neurosci.  2013 Jan 16;33(3):906-13.
    **Journal impact factor: 7.115    Number of times cited: 10

  6. Walker MP, LaFerla FM, Oddo S, Brewer GJ.  Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease.  Age (Dordr). 2013 Jun;35(3):519-31
    **Journal impact factor: 6.28    Number of times cited: 19


2012

  1. Yan XX, Cai Y, Shelton J, Deng SH, Luo XG, Oddo S, LaFerla FM, Cai H, Rose GM, Patrylo PR.  Chronic Temporal Lobe Epilepsy Is Associated with Enhanced Alzheimer-Like Neuropathology in 3×Tg-AD Mice.  PLoS One. 2012;7(11):e48782.
    **Journal impact factor: 4.092    Number of times cited: 7

  2. Klionsky DJ, Abdalla FC, Abeliovich H, ….. Oberley TD, Oddo S, Ogawa M, … Zuckerbraun B.  Guidelines for the use and interpretation of assays for monitoring autophagy.  Autophagy.  2012 April. 8(4):445-544.
    **Journal impact factor: 7.453    Number of times cited: 2582

  3. Takamura A, Sato Y, Watabe D, Okamoto Y, Nakata T, Kawarabayashi T, Oddo S, LaFerla FM, Shoji M, Matsubara E.  Sortilin is required for toxic action of Aβ oligomers (AβOs): Extracellular AβOs trigger apoptosis, and intraneuronal AβOs impair degradation pathways.  Life Sci. 2012 Dec 10;91(23-24):1177-86
    **Journal impact factor: 2.451    Number of times cited: 9

  4. Cotella D, Hernandez Enriquez B, Wu X, Li R, Pan Z, Leveille J, Link C, Oddo S, and Sesti F.  Toxic role of K+ channel oxidation in mammalian brain (in press).  J Neurosci. 2012 Mar 21;32(12):4133-4144 
    **Journal impact factor: 7.27Number of times cited: 27

  5. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S.  Life-long rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and NMDA signaling. Aging Cell. 2012 Apr;11(2):326-35
    **Journal impact factor: 7.15Number of times cited: 51

  6. Oddo S. The role of mTOR signaling in Alzheimer disease. Frontiers in Bioscience (Schol Ed). 2012 Jan 1;4:941-52.
    **Journal impact factor: 4.05Number of times cited: 29

  7. Caccamo A, Majumder S, Oddo S. Cognitive decline typical of FTLD in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43.  Am J Pathol. 2012 Jan;180(1):293-302. Epub 2011 Nov 7
    **Journal impact factor: 5.22Number of times cited: 17


2011

  1. Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits.  PLoS ONE 2011;6(9):e25416. Epub 2011 Sep 28.
    **Journal impact factor: 4.41Number of times cited: 93

  2. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, Oddo S, LaFerla FM, Struble RG, Rose GM, Patrylo PR, Yan XX. BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer‘s Disease: Differential Aβ Antibody Labeling of Early-Onset Axon Terminal Pathology. Neurotox Res 2012 Feb;21(2):160-74. Epub 2011 Jul 2
    **Journal impact factor: 3.01Number of times cited: 21

  3. Bianchi FT, Camera P, Ala U, Imperiale D, Migheli A, Boda E, Tempia F, Berto G, Bosio Y, Oddo S, LaFerla FM, Taraglio S, Dotti CG, Di Cunto F. The Collagen Chaperone HSP47 Is a New Interactor of APP that Affects the Levels of Extracellular Beta-Amyloid Peptides. PLoS One 2011 Jul;6(7):22370-22370.
    **Journal impact factor: 4.41Number of times cited: 7

  4. Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magrí A, Oddo S. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem 2011 Mar;286(11):8924-8932.
    **Journal impact factor: 5.33Number of times cited: 39

  5. Medina DX, Caccamo A, Oddo S. Methylene blue reduces Aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 2011 Mar;21(2):140-149.
    **Journal impact factor: 4.74Number of times cited: 88


2010

  1. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer‘s disease. Proc Natl Acad Sci U S A 2010 Dec;107(52):22687-22692.
    **Journal impact factor: 9.77Number of times cited: 93

  2. Caccamo A, Magrí A, Oddo S. Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation. Mol Neurodegener 2010 Nov;5:51-51.
    **Journal impact factor: 5.36Number of times cited: 19

  3. Nakashima AS, Oddo S, LaFerla FM, Dyck RH. Experience-dependent regulation of vesicular zinc in male and female 3xTg-AD mice. Neurobiol Aging 2010 Apr;31(4):605-613.
    **Journal impact factor: 6.63Number of times cited: 8

  4. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 2010 Apr;285(17):13107-13120.
    **Journal impact factor: 5.33Number of times cited: 249

  5. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, Seidah NG, Oddo S, LaFerla FM, Spencer TA, Hickey WF, Chang TY. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A 2010 Feb;107(7):3081-3086.
    **Journal impact factor: 9.77Number of times cited: 53


2009

  1. Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J Biol Chem 2009 Oct;284(40):27416-27424.
    **Journal impact factor: 5.33Number of times cited: 74

  2. Oddo S, Caccamo A, Cheng D, LaFerla FM. Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol 2009 Jul;19(3):421-430.
    **Journal impact factor: 4.74Number of times cited: 15

  3. Ouellet M, Emond V, Chen CT, Julien C, Bourasset F, Oddo S, LaFerla F, Bazinet RP, Calon F. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem Int 2009 Dec;55(7):476-82. Epub 2009 May 13.
    **Journal impact factor: 3.60Number of times cited: 73

  4. Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP, Hersh LB. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer‘s disease. J Neurosci Res. 2009 May;87(6):1462-1473.
    **Journal impact factor: 2.96Number of times cited: 44

  5. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer‘s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009 Apr;34(1):163-177.
    **Journal impact factor: 5.12Number of times cited: 105

  6. Bourasset F, Mélissa O, Tremblay C, Julien C, Do TM, Oddo S, LaFerla F, Calon F. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer‘s disease. Neuropharmacology 2009 Mar;56(4):808-813.
    **Journal impact factor: 4.68Number of times cited: 38

  7. Nuntagij P, Oddo S, LaFerla FM, Kotchabhakdi N, Ottersen OP, Torp R. Amyloid deposits show complexity and intimate spatial relationship with dendrosomatic plasma membranes: an electron microscopic 3D reconstruction analysis in 3xTg-AD mice and aged canine. J Alzheimers Dis 2009 Feb;16(2):315-323.
    **Journal impact factor: 4.26Number of times cited: 15

  8. Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, Choi CH, McBride SM, Faber DS. Validation of a 2-day water maze protocol in mice. Behav Brain Res 2009 Jan;196(2):220-227.
    **Journal impact factor: 3.34Number of times cited: 33


2008

  1. Janelsins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 2008 Dec;173(6):1768-1782.
    **Journal impact factor: 5.22Number of times cited: 76

  2. Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci 2008 Nov;28(47):12163-12175.
    **Journal impact factor: 7.27Number of times cited: 88

  3. Rodríguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, LaFerla FM, Oddo S, Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer‘s disease. PLoS One 2008 Aug;3(8):2935-2935.
    **Journal impact factor: 4.41Number of times cited: 163

  4. Lopez JR, Lyckman A, Oddo S, LaFerla FM, Querfurth HW, Shtifman A. Increased intraneuronal resting [Ca2+] in adult Alzheimer‘s disease mice. J Neurochem 2008 Apr;105(1):262-271.
    **Journal impact factor: 4.38Number of times cited: 76

  5. Oddo S. The ubiquitin-proteasome system in Alzheimer‘s disease. J Cell Mol Med 2008 Apr;12(2):363-373.
    **Journal impact factor: 4.60Number of times cited: 128

  6. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 2008 May 1;1207:225-36. Epub 2008 Feb 16.
    **Journal impact factor: 2.62Number of times cited: 130

  7. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, LaFerla FM, Jin LW. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem 2008 Jan;104(2):457-468.
    **Journal impact factor: 4.38Number of times cited: 107


2007

  1. Giménez-Llort L, Blázquez G, Cañete T, Johansson B, Oddo S, Tobeña A, LaFerla FM, Fernández-Teruel A. Modeling behavioral and neuronal symptoms of Alzheimer‘s disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 2007;31(1):125-47.
    **Journal impact factor: 9.01Number of times cited: 113

  2. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci 2007 Nov;27(48):13357-13365.
    **Journal impact factor: 7.27Number of times cited: 169

  3. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhratsky A, Oddo S, LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer‘s disease progression. J Neurochem 2007 Nov;103(3):1132-1144.
    **Journal impact factor: 4.38Number of times cited: 92

  4. Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFerla FM. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci 2007 Oct;27(44):11925-11933.
    **Journal impact factor: 7.27Number of times cited: 98

  5. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis 2007 Oct;28(1):76-82.
    **Journal impact factor: 5.12Number of times cited: 108

  6. Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem 2007 Aug;102(4):1053-1063.
    **Journal impact factor: 4.38Number of times cited: 60

  7. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer‘s disease. Nat Rev Neurosci 2007 Jul;8(7):499-509.
    **Journal impact factor: 29.51Number of times cited: 892

  8. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007 May;170(5):1669-1675.
    **Journal impact factor: 5.22Number of times cited: 131

  9. Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, LaFerla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer‘s mouse models. Ann N Y Acad Sci 2007 Feb;1097:265-277.
    **Journal impact factor: 2.85Number of times cited: 66


2006

  1. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem 2006 Dec;281(51):39413-39423.
    **Journal impact factor: 5.33Number of times cited: 232

  2. Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer‘s disease. J Neurosci 2006 Dec;26(51):13384-13389.
    **Journal impact factor: 7.27Number of times cited: 92

  3. Stutzmann GE, Smith I, Caccamo A, Oddo S, LaFerla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer‘s disease mice. J Neurosci 2006 May;26(19):5180-5189.
    **Journal impact factor: 7.27Number of times cited: 167

  4. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006 Mar;49(5):671-682.
    **Journal impact factor: 14.03Number of times cited: 303

  5. Oddo S, LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer‘s disease. J Physiol Paris 2006 Mar;99(2-3):172-179.
    **Journal impact factor: 3.03Number of times cited: 96

  6. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 2006 Jan;281(3):1599-1604.
    **Journal impact factor: 5.33Number of times cited: 310

  7. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol 2006 Jan;168(1):184-194.
    **Journal impact factor: 5.22Number of times cited: 166


2005

  1. Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer‘s disease mice. J Neuroinflammation 2005 Oct;2:23-23.
    **Journal impact factor: 5.79Number of times cited: 125

  2. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer‘s disease. J Neurosci 2005 Sep;25(39):8843-8853.
    **Journal impact factor: 7.27Number of times cited: 301

  3. Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer‘s disease. J Neurochem 2005 Sep;94(6):1711-1718.
    **Journal impact factor: 4.38Number of times cited: 110

  4. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 2005 May;26(5):645-654.
    **Journal impact factor: 5.12Number of times cited: 215

  5. LaFerla FM, Oddo S. Alzheimer‘s disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 2005 Apr;11(4):170-176.
    **Journal impact factor: 10.31Number of times cited: 286

  6. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer‘s disease-related cognitive deficits in transgenic mice. Neuron 2005 Mar;45(5):675-688.
    **Journal impact factor: 14.03Number of times cited: 759

  7. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, Leslie FM, LaFerla FM. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A 2005 Feb;102(8):3046-3051.
    **Journal impact factor: 9.77Number of times cited: 168


2004

  1. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004 Aug;43(3):321-332.
    **Journal impact factor: 14.03Number of times cited: 689

  2. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004 Jul;114(1):121-130.
    **Journal impact factor: 14.15Number of times cited: 321

  3. Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest 2004 Feb;113(4):582-590.
    **Journal impact factor: 14.15Number of times cited: 65


2003

  1. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer‘s disease. Neurobiol Aging 2003 Dec;24(8):1063-1070.
    **Journal impact factor: 6.63Number of times cited: 594

  2. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer‘s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003 Jul;39(3):409-421.
    **Journal impact factor: 14.03Number of times cited: 1992


2002

Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A 2002 Apr;99(9):6334-6339.
**Journal impact factor: 9.77Number of times cited: 103